Immunosuppressive and anti-TNF therapy in IBD cause dermatological adverse effects, including skin infections, drug hypersensitivity, psoriasis, eczema, and nonmelanomatous skin cancer [18, 19]. This evidence concerns the gene TNF and inflammatory bowel disease.